LOGIN  |  REGISTER
Compass Therapeutics

Baxter to Present at BofA Securities 2023 Health Care Conference

April 19, 2023 | Last Trade: US$32.87 0.55 -1.65

DEERFIELD, Ill. / Apr 19, 2023 / Business Wire / Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the BofA Securities 2023 Health Care Conference on Tuesday, May 9, 2023. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 1:00 p.m. Eastern Time.

The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through November 5, 2023.

About Baxter

Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook.

Viking Therapeutics

Stock Quote

Last Trade: US$32.87
Daily Change: -0.55 -1.65
Daily Volume: 3,688,700
Market Cap: US$16.780B

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB